Evidence map›Paper›PMID 38816141›Full record

Observational studyThe lancet. HIV2024

Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study.

Maria Salgado, Cristina Gálvez, Monique Nijhuis, Mi Kwon, E Fabian Cardozo-Ojeda, Jon Badiola, Matthew J Gorman, Laura E P Huyveneers, Victor Urrea, Alessandra Bandera and 26 more

Abstract readObservational Study
In one paragraph

Observational study in The lancet. HIV, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. New hope for cure of HIV-infected patients.Infectious diseases & immunity · 2025
    Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Maria SalgadoIrsiCaixa, Badalona, Spain; Germans Trias i Pujol Research Institute, Badalona, Spain; Centro de Investigación Biomédica en Red en Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain. Electronic address: msalgado@irsicaixa.es.
Cristina GálvezIrsiCaixa, Badalona, Spain.
Monique NijhuisTranslational Virology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands; HIV Pathogenesis Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
Mi KwonDepartment of Hematology, Hospital Universitario Gregorio Marañón, Institute of Health Research Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
E Fabian Cardozo-OjedaVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Xencor, Pasadena, CA, USA.
Jon BadiolaUniversity Hospital Virgen de las Nieves, Granada, Spain.
Matthew J GormanRagon Institute of Mass General, MIT, and Harvard, Cambridge, MA, USA; Moderna Therapeutics, Cambridge, MA, USA.
Laura E P HuyveneersTranslational Virology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands.
Victor UrreaIrsiCaixa, Badalona, Spain.
Alessandra BanderaInfectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Björn-Erik Ole JensenDepartment of Gastroenterology, Hepatology, and Infectious Diseases, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.
Linos VandekerckhoveHIV Cure Research Center, Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent University, Ghent, Belgium.
Manuel JuradoUniversity Hospital Virgen de las Nieves, Granada, Spain.
Kavita RajKings College Hospital, London, UK.
Julian Schulze Zur WieschInfectious Diseases Unit, Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.
Rebeca BailénDepartment of Hematology, Hospital Universitario Gregorio Marañón, Institute of Health Research Gregorio Marañón, Madrid, Spain.
Johanna M EberhardInfectious Diseases Unit, Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany; Helmholtz Institute for One Health, Greifswald, Germany.
Mitja NabergojDivision of Hematology, Hôpitaux Universitaires de Genève, Geneva, Switzerland; Hematology Service, Institut Central des Hôpitaux, Sion, Switzerland.
Gero HütterDKMS Collection Center, Dresden, Germany.
Raquel Saldaña-MorenoHospital General de Jerez de la Frontera, Cádiz, Spain.
Sharon OldfordNova Scotia Health, Dalhousie University, Halifax, NS, Canada.
Lisa BarrettNova Scotia Health, Dalhousie University, Halifax, NS, Canada.
Maria Luisa Montes RamirezCentro de Investigación Biomédica en Red en Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain; University Hospital La Paz, IdiPAZ, Madrid, Spain.
Salisu GarbaVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Merck, Rahway, NJ, USA.
Ravi Kumar GuptaDepartment of Medicine, University of Cambridge, Cambridge, UK.
Boris RevolloDepartment of Infectious Diseases, University Hospital Germans Trias i Pujol, Institut Català d'Oncologia, Badalona, Spain.
Christelle Ferra-CollDepartment of Hematology, University Hospital Germans Trias i Pujol, Institut Català d'Oncologia, Badalona, Spain; University of Vic-Central University of Catalonia, Vic, Spain.
Jurgen KuballDepartment of Hematology and Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands.
Galit AlterRagon Institute of Mass General, MIT, and Harvard, Cambridge, MA, USA; Moderna Therapeutics, Cambridge, MA, USA.
Asier Sáez-CiriónViral Reservoirs and Immune Control Unit, Institut Pasteur, Université Paris Cité, Paris, France.
Jose Luis Diez-MartinDepartment of Hematology, Hospital Universitario Gregorio Marañón, Institute of Health Research Gregorio Marañón, Madrid, Spain.
Elizabeth R DukeVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Medicine, Allergy and Infectious Diseases Division, University of Washington, WA, Seattle, USA.
Joshua T SchifferVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Medicine, Allergy and Infectious Diseases Division, University of Washington, WA, Seattle, USA.
Annemarie WensingTranslational Virology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands; Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Javier Martinez-PicadoIrsiCaixa, Badalona, Spain; Germans Trias i Pujol Research Institute, Badalona, Spain; Centro de Investigación Biomédica en Red en Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain; University of Vic-Central University of Catalonia, Vic, Spain; Catalan Institution for Research and Advanced Studies, Barcelona, Spain. Electronic address: jmpicado@irsicaixa.es.
IciStem Consortium

Funding

Reversing Immune Dysfunction for HIV-1 EradicationUM1AI164561 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SUMIT K CHANDA, Paula M Cannon · 2021 to 2026
$30.0M
MultiOMICS to uncover immune and virological mechanisms that drive HIV DNA decay, restore immune homeostasis, and promote HIV specific immunity in PWH receiving cell therapies.P01AI178376 · NIAID · EMORY UNIVERSITY · PI Rafick Pierre Sekaly · 2023 to 2026
$6.1M
Mathematical modeling of optimal therapeutic combinations for HIV cureR01AI150500 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SCHIFFER, JOSHUA TISDELL · 2020 to 2024
$2.3M
European Research CouncilNIAID NIH HHS P01 AI178376NIAID NIH HHS R01 AI150500NIAID NIH HHS UM1 AI164561
6 · The paper itself

Abstract

backgroundAllogeneic haematopoietic stem-cell transplantation (allo-HSCT) markedly reduces HIV reservoirs, but the mechanisms by which this occurs are only partly understood. In this study, we aimed to describe the dynamics of virological and immunological markers of HIV persistence after allo-HSCT.

methodsIn this prospective observational cohort study, we analysed the viral reservoir and serological dynamics in IciStem cohort participants with HIV who had undergone allo-HSCT and were receiving antiretroviral therapy, ten of whom had received cells from donors with the CCR5Δ32 mutation. Participants from Belgium, Canada, Germany, Italy, the Netherlands, Spain, Switzerland, and the UK were included in the cohort both prospectively and retrospectively between June 1, 2014 and April 30, 2019. In the first 6 months after allo-HSCT, participants had monthly assessments, with annual assessments thereafter, with the protocol tailored to accommodate for the individual health status of each participant. HIV reservoirs were measured in blood and tissues and HIV-specific antibodies were measured in plasma. We used the Wilcoxon signed-rank test to compare data collected before and after allo-HSCT in participants for whom longitudinal data were available. When the paired test was not possible, we used the Mann-Whitney U test. We developed a mathematical model to study the factors influencing HIV reservoir reduction in people with HIV after allo-HSCT.

findingsWe included 30 people with HIV with haematological malignancies who received a transplant between Sept 1, 2009 and April 30, 2019 and were enrolled within the IciStem cohort and included in this analysis. HIV reservoirs in peripheral blood were reduced immediately after full donor chimerism was achieved, generally accompanied by undetectable HIV-DNA in bone marrow, ileum, lymph nodes, and cerebrospinal fluid, regardless of donor CCR5 genotype. HIV-specific antibody levels and functionality values declined more slowly than direct HIV reservoir values, decaying significantly only months after full donor chimerism. Mathematical modelling suggests that allogeneic immunity mediated by donor cells is the main viral reservoir depletion mechanism after massive reservoir reduction during conditioning chemotherapy before allo-HSCT (half-life of latently infected replication-competent cells decreased from 44 months to 1·5 months).

interpretationOur work provides, for the first time, data on the effects of allo-HSCT in the context of HIV infection. Additionally, we raise the question of which marker can serve as the last reporter of the residual viraemia, postulating that the absence of T-cell immune responses might be a more reliable marker than antibody decline after allo-HSCT.

fundingamfAR (American Foundation for AIDS Research; ARCHE Program), National Institutes of Health, National Institute of Allergy and Infectious Diseases, and Dutch Aidsfonds.

Indexed as

Hematopoietic Stem Cell TransplantationHIV InfectionsAdultBiomarkersFemaleHIV-1HIV AntibodiesHumansMaleMiddle AgedProspective StudiesTransplantation, HomologousViral LoadBiomarkersHIV Antibodies

Identifiers

PMID38816141
PMCPMC11417461

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.